ID
22164
Description
The present pharmacokinetic study is designed to assess the pharmacokinetics of RSG XR as monotherapy in patients with mild Alzheimer's disease (AD) as such information will not be obtained from the current phase III trials . The study aims to enroll fourteen patients (seven of each APOE genotype). Each patient will receive a single oral dose of 4mg of RSG XR in the morning under fasted conditions and PK samples will be taken up to 36h. GSK Source & Descriptions: https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT00688207?term=NCT00688207&rank=1
Keywords
Versions (3)
- 5/8/17 5/8/17 -
- 5/15/17 5/15/17 -
- 5/22/17 5/22/17 -
Uploaded on
May 22, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Screening Urinalysis Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Screening Urinalysis Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
Similar models
Screening Urinalysis Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone NCT00688207 / GSK-AVA109941
C0042014 (UMLS CUI-2)
C0042014 (UMLS CUI [2,1])
C0040223 (UMLS CUI [2,2])
C2826772 (UMLS CUI-2)
C0042014 (UMLS CUI [1,2])
C2826772 (UMLS CUI-2)